Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nebulised gentamicin-suitable for childhood bronchiectasis.

Jacob Twiss1, Cass Byrnes, Roger Johnson

  • 1Department of Paediatrics, University of Auckland, Starship Respiratory Service, Starship Children's Health, Private Bag 92024, Auckland, New Zealand. jtwiss@ihug.co.nz

International Journal of Pharmaceutics
|April 26, 2005
PubMed
Summary

Nebulised gentamicin in saline is safe and effective for children with non cystic fibrosis bronchiectasis. This antibiotic therapy achieves bactericidal sputum concentrations with minimal systemic absorption, improving respiratory health.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with transplant workup completion in a regional kidney program in Ontario, Canada: a retrospective cohort study.

Frontiers in nephrology·2026
Same author

Evaluation of a Collaborative Practice Agreement Intervention to Improve Access to HIV Prevention Services in Southeastern US Pharmacies: Protocol for a Hybrid Type 1 Effectiveness-Implementation Study.

JMIR research protocols·2026
Same author

Antibacterial activity of green-synthesized silver nanoparticles against Gram-negative bacteria and insights into potential resistance mechanisms.

INNOSC theranostics & pharmacological sciences·2026
Same author

Intestinal colonisation with extended-spectrum beta-lactamase-producing Enterobacterales and the impact of selected factors on intestinal colonisation duration: a prospective cohort study.

Antimicrobial resistance and infection control·2025
Same author

An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors.

ACS pharmacology & translational science·2025
Same author

Gallium Resistance in <i>Staphylococcus aureus</i>: Polymorphisms and Morphology Impacting Growth in Metals, Antibiotics and Polyfluorinated Compounds.

Applied microbiology (Basel, Switzerland)·2025

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Respiratory Medicine

Background:

  • Nebulised antibiotic therapy is a proven treatment for cystic fibrosis patients with Pseudomonas infections.
  • Its efficacy and safety in children with non-cystic fibrosis bronchiectasis remain unevaluated.
  • This study addresses the need to assess this treatment in a similar pediatric respiratory condition.

Purpose of the Study:

  • To evaluate the suitability of gentamicin nebulisation for children with non-cystic fibrosis bronchiectasis.
  • To assess the safety and efficacy of a specific gentamicin solution and nebuliser combination.
  • To determine if this therapy can achieve therapeutic concentrations in sputum.

Main Methods:

  • A PARI LC plus nebuliser and PARI Turboboy N compressor delivered 4 mL of gentamicin (80 mg) in saline.

Related Experiment Videos

  • Solution characteristics (pH, osmolarity, chloride) and aerosol particle size were analyzed.
  • Ten children with non-cystic fibrosis bronchiectasis received treatment, with sputum and serum gentamicin levels measured, alongside pulmonary function tests.

    • Main Results:

    • The gentamicin solution had an osmolarity of 199 mOsm/L and pH of 4.1.
    • Nebulisation was well-tolerated, with no significant impact on FEV1 (Forced Expiratory Volume in 1 second).
    • Peak serum gentamicin levels were minimal (0.3 mg/L), while mean sputum concentrations (624 mg/g) exceeded 25 times the minimum inhibitory concentration for Haemophilus influenzae.

    Conclusions:

    • Nebulising 80 mg of gentamicin in saline is well-tolerated in children with non-cystic fibrosis bronchiectasis.
    • The therapy achieves bactericidal concentrations in sputum.
    • Negligible systemic absorption suggests gentamicin is a suitable inhaled antibiotic option for this patient group.